| Identification | Back Directory | [Name]
p- Cresol sulfate ammonium salt | [CAS]
3233-58-7 | [Synonyms]
p-Cresyl sulfate
(4-methylphenyl) sulfate
p- Cresol sulfate ammonium salt
Sulfuric acid, mono(4-methylphenyl) ester | [Molecular Formula]
C7H8O4S | [MDL Number]
MFCD27964764 | [MOL File]
3233-58-7.mol | [Molecular Weight]
188.2 |
| Hazard Information | Back Directory | [Uses]
p-Cresyl sulfate (p-Tolyl sulfate) is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate shows antiproliferation activity. p-Cresyl sulfate increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate activates the JNK and p38 MAPK signaling pathways[1][2][3]. | [Definition]
ChEBI:P-cresol sulfate is an aryl sulfate that is p-cresol in which the phenolic hydrogen has been replaced by a sulfo group. It has a role as a human metabolite, a uremic toxin and a gut flora metabolite. It is functionally related to a p-cresol. It is a conjugate acid of a p-cresol sulfate(1-). | [in vivo]
p-Cresyl sulfate (10 mg/kg; IP; twice daily for 4 weeks) exhibits hyperglycemia and hypercholesterolemia[2]. | Animal Model: | CD1 Swiss mice[2] | | Dosage: | 10 mg/kg | | Administration: | IP; twice daily for 4 weeks | | Result: | Increased the fasting plasma glucose concentration, plasma cholesterol levels were increased by >50% compared with vehicle mice, Induced insulin resistance. |
| [IC 50]
Microbial Metabolite; Human Endogenous Metabolite | [References]
[1] Wu TK, et al. The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1α axis signals. Sci Rep. 2019 Mar 1;9(1):3207. DOI:10.1038/s41598-019-39646-9
[2] Koppe L, et al. p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol. 2013 Jan;24(1):88-99. DOI:10.1681/ASN.2012050503
[3] Tanaka H, et al. p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Bone. 2013 Oct;56(2):347-54. DOI:10.1016/j.bone.2013.07.002 |
|
|